gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes/expands neoantigen-specific CD8+ T cells, which recognize the neoantigen peptide–HLA class I complex on tumor cells and kill them via perforin/granzyme and Fas–FasL pathways; the vaccine itself is not cytotoxic.
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
Presented via HLA-A/HLA-B/HLA-C to CD8+ T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06195384
disease_id_num_tar_ref
2786
drug_id_num_tar_ref
7437